Daiwa Securities Group Inc. Biogen Inc. Transaction History

Daiwa Securities Group Inc.

$18.8 Billion
Q2 2024

A detailed history of Daiwa Securities Group Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 24,848 shares of BIIB stock, worth $4.32 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

24,848

Previous 22,651 9.7%

Holding current value

$4.32 Million

Previous $4.88 Million 17.94%

% of portfolio

0.03%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$190.52 - $236.72 $418,572 - $520,073	2,197 Added 9.7%	24,848 $5.76 Million
Q1 2024 May 02, 2024	BUY	$212.02 - $267.71 $460,507 - $581,466	2,172 Added 10.61%	22,651 $4.88 Million
Q4 2023 Jan 31, 2024	SELL	$222.59 - $267.94 $1.47 Million - $1.77 Million	-6,600 Reduced 24.37%	20,479 $5.3 Million
Q3 2023 Nov 01, 2023	BUY	$253.3 - $285.89 $2.14 Million - $2.41 Million	8,442 Added 45.3%	27,079 $6.87 Million
Q2 2023 Jul 31, 2023	BUY	$275.25 - $318.06 $139,827 - $161,574	508 Added 2.8%	18,637 $5.31 Million
Q1 2023 May 02, 2023	BUY	$256.56 - $292.34 $476,945 - $543,460	1,859 Added 11.43%	18,129 $5.04 Million
Q4 2022 Feb 06, 2023	BUY	$252.44 - $306.72 $105,015 - $127,595	416 Added 2.62%	16,270 $4.51 Million
Q3 2022 Nov 02, 2022	SELL	$194.69 - $268.46 $198,194 - $273,292	-1,018 Reduced 6.03%	15,854 $4.23 Million
Q2 2022 Aug 09, 2022	BUY	$187.54 - $223.02 $118,712 - $141,171	633 Added 3.9%	16,872 $3.44 Million
Q1 2022 Apr 29, 2022	BUY	$193.77 - $244.14 $334,640 - $421,629	1,727 Added 11.9%	16,239 $3.42 Million
Q4 2021 Feb 03, 2022	BUY	$223.92 - $287.77 $354,913 - $456,115	1,585 Added 12.26%	14,512 $3.48 Million
Q3 2021 Nov 05, 2021	BUY	$282.99 - $369.05 $193,282 - $252,061	683 Added 5.58%	12,927 $3.66 Million
Q2 2021 Aug 06, 2021	SELL	$259.0 - $414.71 $1.21 Million - $1.94 Million	-4,667 Reduced 27.6%	12,244 $4.24 Million
Q1 2021 May 03, 2021	BUY	$242.95 - $284.63 $1.23 Million - $1.44 Million	5,058 Added 42.67%	16,911 $4.73 Million
Q4 2020 Feb 04, 2021	BUY	$236.26 - $355.63 $6,379 - $9,602	27 Added 0.23%	11,853 $2.9 Million
Q3 2020 Nov 02, 2020	SELL	$264.77 - $305.71 $59,043 - $68,173	-223 Reduced 1.85%	11,826 $3.36 Million
Q2 2020 Aug 11, 2020	BUY	$258.66 - $342.55 $222,447 - $294,593	860 Added 7.69%	12,049 $3.77 Million
Q1 2020 May 14, 2020	BUY	$268.85 - $341.04 $373,970 - $474,386	1,391 Added 14.2%	11,189 $3.54 Million
Q4 2019 Jan 31, 2020	SELL	$220.06 - $304.07 $30,808 - $42,569	-140 Reduced 1.41%	9,798 $2.91 Million
Q3 2019 Nov 04, 2019	BUY	$217.44 - $243.88 $297,457 - $333,627	1,368 Added 15.96%	9,938 $2.31 Million
Q2 2019 Jul 24, 2019	SELL	$219.29 - $241.72 $282,226 - $311,093	-1,287 Reduced 13.06%	8,570 $2 Million
Q1 2019 Apr 26, 2019	SELL	$216.71 - $338.96 $488,897 - $764,693	-2,256 Reduced 18.62%	9,857 $2.33 Million
Q4 2018 Feb 05, 2019	SELL	$278.5 - $352.75 $1.59 Million - $2.01 Million	-5,712 Reduced 32.04%	12,113 $3.65 Million
Q3 2018 Nov 01, 2018	BUY	$293.51 - $383.83 $2.34 Million - $3.06 Million	7,970 Added 80.87%	17,825 $6.3 Million
Q2 2018 Jul 30, 2018	BUY	$257.52 - $306.91 $72,105 - $85,934	280 Added 2.92%	9,855 $2.86 Million
Q1 2018 May 02, 2018	BUY	$260.13 - $367.91 $422,711 - $597,853	1,625 Added 20.44%	9,575 $2.62 Million
Q4 2017 Feb 06, 2018	BUY	$307.64 - $344.58 $44,300 - $49,619	144 Added 1.84%	7,950 $2.53 Million
Q3 2017 Nov 02, 2017	BUY	$281.15 - $329.69 $2.19 Million - $2.57 Million	7,806	7,806 $2.45 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.

Account

Daiwa Securities Group Inc. Biogen Inc. Transaction History